论文部分内容阅读
目的:探讨超声引导经皮射频消融治疗肝癌的疗效及影响疗效的因素。方法:回顾性分析我院超声引导经皮射频消融治疗的50例肝癌患者临床资料,采用四川绵阳立德LDRF-120S多极射频消融仪,电极成伞形张开,治疗的功率以及电极张开大小由计算机控制,在肿瘤消融后,该仪器的治疗自动停止。结果:50例肝癌患者在超声引导经皮射频消融治疗方式下顺利完成治疗,1、2、3年的生存率分别达到85.6%、57.3%、50.2%,患者肿瘤消融比较明显。结论:肿瘤的大小以及位置会影响到射频消融治疗肝癌的效果,但是采用超声引导经皮射频消融治疗肝癌可以有效提升患者的存活时间,减少患者痛苦。
Objective: To investigate the therapeutic effect of ultrasound-guided percutaneous radiofrequency ablation on hepatocellular carcinoma (HCC) and its influencing factors. Methods: The clinical data of 50 patients with HCC who underwent ultrasound-guided percutaneous radiofrequency catheter ablation were retrospectively analyzed. The electrodes were opened with an umbrella shape using the LDRF-120S multi-pole radiofrequency ablation instrument in Mianyang, Sichuan Province. The power of the treatment and the electrode open The size is controlled by a computer and the treatment of the instrument stops automatically after the tumor has been ablated. Results: Fifty patients with HCC were successfully treated with ultrasound-guided percutaneous radiofrequency ablation. The survival rates of one, two and three years were 85.6%, 57.3% and 50.2% respectively. The tumor ablation was more obvious. Conclusion: The size and location of the tumor will affect the radiofrequency ablation of liver cancer. However, the use of ultrasound-guided percutaneous radiofrequency ablation for the treatment of liver cancer can effectively improve the patient’s survival time and reduce the patient’s pain.